Celator Pharmaceuticals Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011
Total Revenue - - -
Cost of Revenue - - -
Gross Profit - - -
Operating Expenses
Research and Development 9,423 4,869 10,607
Sales, General and Admin. 4,867 2,636 3,527
Non-Recurring Items - - -
Other 198 412 442
Operating Income (14,614) (8,000) (15,149)
Income From Continuing Operations
Add'l Income/Expense Items (7,622) (92) (480)
Earnings Before Interest and Tax (22,109) (8,009) (15,055)
Interest Expense 147 4,264 79
Earnings Before Tax (22,256) (12,272) (15,135)
Income Tax (1,412) (1,364) (975)
Minority Interest - - -
Equity Earnings Unconsolidated Subsidiary - - -
Net Income Cont. Operations (20,844) (10,909) (14,160)
Non Recurring Events
Discontinued Operations - - -
Extraordinary Items - - -
Effect of Accounting Changes - - -
Other Items - - -
Net Income (20,844) (10,909) (14,160)
Preferred Stock and Other Adjustments - - -
Net Income Applicable to Common Shareholders (20,844) (10,909) (14,160)